Scientific Research Explores Enzyme Inhibitors to Combat Tuberculosis
An international study investigates novel molecules capable of targeting a vital bacterial enzyme to overcome drug resistance.
Researchers from the Center for Research in Bacterial Biology and Bacteriophages, based at the University of São Paulo, in collaboration with French and American institutions, are investigating new options for tuberculosis treatment by focusing on essential bacterial enzymes.
The study, published in the European Journal of Medicinal Chemistry, examines molecules capable of inhibiting the DNA gyrase enzyme, which is fundamental for organizing the genetic material and ensuring the survival and replication of Mycobacterium tuberculosis.
During the investigation, the team tested approximately 600 small chemical fragments. Out of these, 14 successfully bound to the enzyme, five showed potential to inhibit its activity, and one specific molecule, designated as "compound 9," stood out for its high efficiency in laboratory tests.
According to Nicolas Rossini, a researcher at the Applied Structural Biology to Drugs Laboratory and co-author of the study, the molecule acts distinctively from traditional antibiotics by binding to a previously unexplored region of the enzyme. This mechanism offers a promising starting point to bypass existing antibiotic resistance.
Tuberculosis treatment currently faces significant hurdles, including long therapy durations that can exceed six months and the emergence of resistant strains against established drugs like fluoroquinolones. By attacking a different site on the enzyme, the newly discovered compound aims to circumvent these defense mechanisms and prevent bacterial multiplication.
Márcio Dias, coordinator of the laboratory and another study author, noted that the remaining evaluated molecules also present valuable opportunities for chemical optimization. The research team is currently gathering electronic microscopy data to better understand how these substances interact with the enzyme.
Looking ahead, the researchers plan to develop compounds with even higher inhibitory potency by leveraging artificial intelligence and medicinal chemistry through strategic partnerships. Although further clinical advancements and validation are required before reaching patients, this discovery marks a critical initial step toward developing a new class of antimicrobial medications.